Jump to navigation
The latest clinical and political news for Australian Gastroenterologists
The short treatment duration may benefit groups with poor adherence
Professor Gerald Holtmann on targeting the gastrointestinal biome as a whole.
Machines are starting to outperform clinicians
A spate of hyponatremic incidents has been flagged.
The effect was confined to long-term use or high dosage.
It'll help patients avoid frustrating specialist investigation.
Overall reduced risk and no signs of more aggressive tumours in big study.
Researchers say more study is needed on the role of wheat and FODMAPs.
Age and co-morbidities raise risk of revision.
Multiple factors involved.
The drug has a good safety profile.
Statement of concern issued by ASID.
An immunotherapy treatment for peanut allergy in children produces desensitisation that persists for four years,...
Almost half of the patients who are positive for hepatitis C exposure when screened by their GP do not get follow-up...
Dr David Gillespie, a gastroenterologist and federal politician, reflects on his worst day at...
Pan-genotypic drugs have made treatment easier than ever.
A guide for GPs.
Medical History: Haemorrhoid treatment has come a long way.
Is this the future for colonoscopy?
Despite being free, only a minority of those eligible participate
Australian Doctor Group (ADG) is Australia’s premier business to business publisher, delivering the country’s most recognised industry magazines and websites.
Ensure you never miss a big story by signing up for our daily e-newsletter.